A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.
Roswell Park Researchers Identify New Biomarker of Response to Checkpoint Inhibitors
PRWeb
FacebookTwitterEmail
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other malignancies, according to lead author Fumito Ito, MD, PhD, FACS.
BUFFALO, N.Y. (PRWEB) March 03, 2021
Discovery in lung cancer could help determine which patients will benefit most from immunotherapy
Roswell Park Researchers Identify New Biomarker of Response to Checkpoint Inhibitors prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.